NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations

被引:59
作者
Niederseer, David [1 ]
Wernly, Bernhard [2 ,3 ,4 ]
Aigner, Elmar [5 ]
Stickel, Felix [6 ]
Datz, Christian [7 ]
机构
[1] Univ Zurich, Univ Heart Ctr Zurich, Univ Hosp Zurich, Dept Cardiol, CH-8091 Zurich, Switzerland
[2] Paracelsus Med Univ Salzburg, Dept Anaesthesiol Perioperat Med & Intens Care Me, A-5020 Salzburg, Austria
[3] Paracelsus Med Univ Salzburg, Ctr Publ Hlth & Healthcare Res, A-5020 Salzburg, Austria
[4] Paracelsus Med Univ Salzburg, Dept Cardiol, A-5020 Salzburg, Austria
[5] Paracelsus Med Univ, Dept Med 1, A-5020 Salzburg, Austria
[6] Univ Zurich, Univ Hosp Zurich, Dept Gastroenterol, CH-8091 Zurich, Switzerland
[7] Paracelsus Med Univ, Teaching Hosp, Gen Hosp Oberndorf, Dept Internal Med, A-5110 Oberndorf, Austria
关键词
diabetes; metabolic syndrome; lifestyle; atherosclerosis; NASH; liver; exercise; nutrition; NONALCOHOLIC FATTY LIVER; STEATOHEPATITIS;
D O I
10.3390/jcm10030467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Overwhelming evidence suggests an association of cardiovascular disease (CVD) with non-alcoholic fatty liver disease (NAFLD); however, the underlying mechanisms remain largely speculative. It is, however, likely that common mechanisms contribute to the development of CVD and NAFLD, with lifestyle factors such as smoking, sedentary lifestyle with poor nutrition habits and physical inactivity being major candidates. These behavioral factors, on a predisposing genetic background, trigger changes in gut microbiota, inflammation, dyslipidemia and oxidative stress, leading to metabolic syndrome, diabetes and obesity as well as atherosclerosis. Treatment options to counteract both the progression and development of CVD and NAFLD include lifestyle interventions, optimal medical therapy of comorbid conditions and, as final possibility, bariatric surgery. As no causal pharmacotherapy of NAFLD is available, further research is urgently needed to address the unmet need of a growing population with NAFLD and CVD.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 30 条
[1]   Summary of Revisions: Standards of Medical Care in Diabetes-2019 [J].
不详 .
DIABETES CARE, 2019, 42 :S4-S6
[2]  
Arnett DK, 2019, CIRCULATION, V140, pE563, DOI [10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000677, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.010]
[3]   2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [J].
Cosentino, Francesco ;
Grant, Peter J. ;
Aboyans, Victor ;
Bailey, Clifford J. ;
Ceriello, Antonio ;
Delgado, Victoria ;
Federici, Massimo ;
Filippatos, Gerasimos ;
Grobbee, Diederick E. ;
Hansen, Tina Birgitte ;
Huikuri, Heikki, V ;
Johansson, Isabelle ;
Juni, Peter ;
Lettino, Maddalena ;
Marx, Nikolaus ;
Mellbin, Linda G. ;
Ostgren, Carl J. ;
Rocca, Bianca ;
Roffi, Marco ;
Sattar, Naveed ;
Seferovic, Petar M. ;
Sousa-Uva, Miguel ;
Valensi, Paul ;
Wheeler, David C. ;
Piepoli, Massimo Francesco ;
Birkeland, Kare, I ;
Adamopoulos, Stamatis ;
Ajjan, Ramzi ;
Avogaro, Angelo ;
Baigent, Colin ;
Brodmann, Marianne ;
Bueno, Hector ;
Ceconi, Claudio ;
Chioncel, Ovidiu ;
Coats, Andrew ;
Collet, Jean-Philippe ;
Collins, Peter ;
Cosyns, Bernard ;
Di Mario, Carlo ;
Fisher, Miles ;
Fitzsimons, Donna ;
Halvorsen, Sigrun ;
Hansen, Dominique ;
Hoes, Arno ;
Holt, Richard I. G. ;
Home, Philip ;
Katus, Hugo A. ;
Khunti, Kamlesh ;
Komajda, Michel ;
Lambrinou, Ekaterini .
EUROPEAN HEART JOURNAL, 2020, 41 (02) :255-323
[4]  
EASL, 2016, OBESITY FACTS, V9, P65, DOI [10.1159/000443344, 10.1016/j.jhep.2015.11.004, 10.1007/s00125-016-3902-y]
[5]  
Pelliccia A, 2021, EUR HEART J, V42, P17, DOI [10.1093/eurheartj/ehaa605, 10.1093/eurheartj/ehaa835]
[6]   Decreased Survival of Subjects with Elevated Liver Function Tests During a 28-Year Follow-Up [J].
Soderberg, Cecilia ;
Stal, Per ;
Askling, Johan ;
Glaumann, Hans ;
Lindberg, Greger ;
Marmur, Joel ;
Hultcrantz, Rolf .
HEPATOLOGY, 2010, 51 (02) :595-602
[7]   Nonalcoholic Fatty Liver Disease and the Heart JACC State-of-the-Art Review [J].
Stahl, Eric P. ;
Dhindsa, Devinder S. ;
Lee, Suegene K. ;
Sandesara, Pratik B. ;
Chalasani, Naga P. ;
Sperling, Laurence S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (08) :948-948
[8]   Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population [J].
Stepanova, Maria ;
Younossi, Zobair M. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (06) :646-650
[9]   NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? [J].
Stols-Goncalves, Daniela ;
Hovingh, G. Kees ;
Nieuwdorp, Max ;
Holleboom, Adriaan G. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (12) :891-902
[10]   Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? [J].
Tacelli, Matteo ;
Celsa, Ciro ;
Magro, Bianca ;
Giannetti, Aurora ;
Pennisi, Grazia ;
Spatola, Federica ;
Petta, Salvatore .
PHARMACEUTICALS, 2018, 11 (04)